New pill aims to plug kidney leaks in rare disease

NCT ID NCT04456816

Recruiting now Disease control Sponsor: SynAct Pharma Aps Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called AP1189 in people with a rare kidney condition called idiopathic membranous nephropathy, which causes severe protein leakage in urine. The trial includes 23 adults who are already on standard blood pressure medications. Participants will receive either AP1189 or a placebo for 12 weeks to see if the drug is safe and can reduce protein loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AP1189
What this could lead to: If successful, AP1189 could offer a new add-on treatment to reduce protein in urine and slow kidney damage in membranous nephropathy patients.
What could go wrong: This is an early Phase 2 trial with only 23 participants, so results may not apply broadly. The drug is added to existing therapy, and its safety and effectiveness are still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates